University of Southampton
Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease
Planning is currently underway for a placebo-controlled trial of the candidate
Roche to advance Parkinson’s disease candidate into phase 3 development
More than ten million people worldwide are living with the neurodegenerative disorder
Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib
The immune-mediated disease affects more than 2.9 million people worldwide
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study
The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use
The neurological disorder affects more than 150,000 people in the UK
International Alzheimer’s disease prevention trial in at-risk young adults begins
The study will evaluate whether the amyloid beta protein can be blocked from ever accumulating in the brain
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
The neurological disorder affects approximately 2.9 million people globally
AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial
More than ten million people worldwide are living with the neurodegenerative disorder
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab
The drug showed benefits across key secondary endpoints, including tau accumulation
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder